TABLE 1.
Incidence of HD, 2011 to 2022
| Location | Study | Cases | Sample (in person‐years) | Incidence per 100,000 person‐years | 95% CI |
|---|---|---|---|---|---|
| Asia (South Korea) | Kim et al, 2015 31 | 29 | 51,141,463 | 0.06 | 0.04–0.08 |
| Europe (Italy) | Carrassi et al, 2017 26 | 2 | 2,000,000 | 0.10 | 0.03–0.24 |
| Europe (Italy) | Kodra et al, 2019 27 | 614 | 180,588,235 | 0.34 | 0.31–0.37 |
| Europe (Italy) | Muroni et al, 2021 28 | 53 | 18,150,685 | 0.29 | 0.21–0.37 |
| Europe (Germany) | Ohlmeier et al, 2019 29 | 60 | 6,651,276 | 0.90 | 0.67–1.13 |
| Europe (Greece) | Panas et al, 2011 30 | 20 | 9,025,974 | 0.22 | 0.12–0.32 |
| Europe (United Kingdom) | Sackley et al, 2011 23 | 13 | 2,964,386 | 0.44 | 0.20–0.68 |
| Europe (Spain) | Sienes Bailo et al, 2020 32 | 4 | 593,387 | 0.67 | 0.01–1.34 |
| Europe (Iceland) | Sveinsson et al, 2012 24 | 8 | 5,714,286 | 0.14 | 0.04–0.24 |
| Europe (United Kingdom) | Wexler et al, 2016 9 | 199 | 29,522,583 | 0.67 | 0.58–0.77 |
| Europe (Spain) | Vicente et al, 2021 33 | 63 | 15,750,000 | 0.40 | 0.30–0.50 |
| Subgroup analysis, Europe (I 2 = 49, Q = 18) | 0.38 | 0.27–0.49 | |||
| North America (United States) | Bruzelius et al, 2019 35 | 267 | 15,198,207 | 1.76 | 1.55–1.97 |
| North America (Canada) | Shaw et al, 2022 12 | 21 | 3,183,874 | 0.66 | 0.38–0.94 |
| Subgroup analysis, North America (I 2 = 0, Q = 1) | 1.21 | 0.14–2.29 | |||
| Pooled estimate (I 2 = 65, Q = 34) | 0.48 | 0.33–0.63 | |||
Abbreviations: HD, Huntington's disease; CI, confidence interval.